

Our Reference: **C19RM 2021 FUNDING_NIGERIA**

Geneva, 17 June 2021

H.E. Dr. E. Osagie Ehanire
Hon. Minister of Health and CCM Chairman
Federal Secretariat Complex Phase 1, Former SGF Office
Abuja, 23409
Federal Republic of Nigeria

Subject: 2021 COVID-19 Response Mechanism Additional Funding for Nigeria

Dear Honorable Minister of Health,

Thank you for your commitment in the fight against the COVID-19 pandemic.

The Global Fund has reviewed your COVID-19 Response Mechanism (**C19RM**) Fast-track Funding Request and approved USD 50,083,594 of additional investments for your country's COVID-19 response (**C19RM Additional Award**). This brings your total C19RM award (including all C19RM 2020 awards received to date) to USD 109,797,575 (**C19RM Total Award**).

Please note that the C19RM Additional Award is additional to your country's 2017-2019 and 2020-2022 allocations and any C19RM funding awarded to your country to date. The C19RM Additional Award will become part of the grant (**Grant**) listed in the table below:

Grant	Amount Awarded USD	Implementation Period dates
NGA – S – NACA	USD 50,083,594	01/04/2021 to 31/12/2023

The Global fund recognizes the importance of scaling-up all critical interventions to control COVID-19 and notes that the COVID-19 testing coverage in the Federal Republic of Nigeria is low compared to other countries in the region. The Global Fund therefore wishes to convey to partners the importance of revising the current testing strategy at the time of submitting the C19RM full funding request. The availability of additional resources is an opportunity for an ambitious proposition to increase access to testing at a larger scale. More specifically, we encourage greater capacity to scale up and use of COVID-19 Rapid Diagnostic Tests (AgRDTs).

Further considerations relating to the C19RM Additional Award were noted during the Global Fund, GAC and CTAG¹ partner review of the C19RM Fast-track Funding Request:

- According to the Global Fund guidelines, some of the items requested within the Fast-track Funding Request are not eligible for the fast-track process. Out of the 34 PPE items which were requested as part of the infection prevention and control intervention only 17 items have been approved. Nevertheless, the Global Fund encourages the CCM to consider including the remaining items as part of C19RM full funding request.
- The PPE requested for fast-track approval is restricted to 133 PCR laboratories and 137 treatment centers. The assumptions adequately factored utilization levels, stock on hand and a reasonable potential wastage rate to estimate the gaps.

¹ Partners of the Grant Approvals Committee (GAC) and COVID-19 technical advisory group comprised of ACT-Accelerator partners (CTAG) review C19RM Funding Requests in parallel with the Global Fund review.

However, the National Agency for the Control of AIDS (NACA), the Principal Recipient, is requested to align the approach to quantification with the approach used by NACA in grant NGA-S-NACA (the "RSSH Grant"). In addition, there is a need to consider needs for mitigation of impact of COVID-19 on disease-specific activities, including community activities, and/or any other major activities including campaigns, to cover gaps for the remainder of 2021 and needs for 2022 and 2023. A more complete overview of the needs and gaps should be presented as part of the C19RM full funding request.

While the deadline for use of the C19RM Additional Award is **31 December 2023**, recipients are expected to use these funds **as soon as possible** to address urgent needs and only for the purposes for which the funding was approved and pursuant to the terms and conditions of the corresponding grant agreements for the Grant (**Grant Agreement**) and this letter.

The C19RM Additional Award must be incorporated into the Grant, along with any additional C19RM funds that may be approved following the Global Fund's review of the country's C19RM Full Funding Request, by no later than two calendar months from the date of issuance of the Notification Letter confirming the C19RM Full Funding Request award (if applicable) or 1.5 months before the current reporting period end-date, whichever is earlier. In the meantime, given the urgency of the nature of the activities for which the C19RM funds were awarded, the Principal Recipient may utilize any available uncommitted funds under the relevant Grant to initiate implementation of the approved C19RM activities in accordance with the terms and conditions of the Grant Agreement and this letter. By initiating implementation of the approved C19RM activities, the relevant Principal Recipient is deemed to have accepted the terms and conditions of the relevant Grant Agreement and this letter.

The Global Fund Country Team will be in touch with each Principal Recipient to discuss the process for initiating implementation of the approved C19RM activities.

We stand ready to support Nigeria in responding to the COVID-19 pandemic, which threatens to destroy years of progress against HIV, TB and malaria. To defeat COVID-19, protect progress against HIV, TB and malaria, and save lives, we must unite to fight.

Yours sincerely



Mark Eldon-Edington
Division Head
Grant Management

Cc: Director General National Agency for the Control of AIDS (NACA)

encl: C19RM HPMT
C19RM Budget

Annex 1
Conditions to use of the C19RM Additional Award

1. In order to address anticipated risks associated with availability of adequate storage space, NACA is requested to: (i) prior to the distribution of PPE, develop and share with the Global Fund a PPE distribution plan; (ii) ensure that deliveries of PPE are staggered to minimize pressure on available storage space; (iii) work with Nigeria Center for Disease Control and other country stakeholders to identify additional secure storage space for PPE; and (iv) leverage the RSSH Grant's work with respect to the upgrade of 12 warehouses to use such warehouses to optimize storage of PPE.
2. To ensure an efficient importation process, NACA is encouraged to support any processes geared to enabling receipt of commodities related to the pandemic response, including by ensuring that commodities are fully registered with relevant regulatory agencies, and accelerating the customs waiver (IDEC) application process.
3. Certain cold chain equipment was exceptionally approved to support the effective management of diagnostics, other laboratory commodities and samples at the peripheral laboratories and treatment centers. This exceptional approval is conditioned on the utilization of such equipment primarily for storage of diagnostics commodities. We also encourage the country to make adequate consideration for voltage stabilizers to ensure the functioning of the equipment as soon it arrives.
4. Given the critical nature of several items requested in the Fast-track funding request, the Global Fund considers the PPM/ Wambo as the main procurement channel for strategic and mainstream health products in line with the C19RM Health Product Segmentation Framework. Nevertheless, the Global Fund recommends that the following items be purchased locally (including associated PSM costs) due to tight international supply: PSA plant, expansion of oxygen piping systems, Liquid Oxygen and Cylinder distribution manifolds, Nasal Cannula, and UPS units. The purchase of such items will require technical support and approval from CHAI and/or WHO (including with respect to appropriate warranties and maintenance). Prior to the purchase of the above listed items, NACA is requested to share, with the Global Fund, a PSA deployment and refurbishment plan.
5. The Principal Recipient acknowledges and agrees that the Global Fund may request the Local Fund Agent and/or the Fiscal Agent to undertake a pre-award review of locally-sourced health products and related services procured under the C19RM Additional Award to ensure that the health products and services procured are value for money and also that the procurements will be conducted in accordance with Article 5 of the Global Fund Grant Regulations (2014). More specifically, the Local Fund Agent and/or the Fiscal Agent will be requested to:
 - i. Ensure purchase requisitions are in line with the specific activity under the approved budget and work-plan and represent value for money;
 - ii. Review and approve requests for compliance with the minimum standards and applicable procurement guidelines/policies;
 - iii. Observe the tender development process in order to ensure it does not favor specific suppliers, and act as an observer in the tender evaluation committee in order to ensure that the process is transparent and fair; and
 - iv. Review supporting documentation with a view to identifying possible red flags of procurement fraud and corruption.
6. C19RM Health Products Reporting
 - a. The Principal Recipient shall adhere to the procurement channel arrangements approved in the enclosed C19RM HPMT for each relevant Grant Agreement, and shall not make any amendments to these arrangements without the prior written approval of the Global Fund.
 - b. No later than the tenth (10th) day of each calendar month of the Implementation Period, the Principal Recipient shall complete and submit to the Global Fund's satisfaction, the

C19RM Procurement Progress Reporting Template (template forthcoming) setting out for each C19RM Strategic Health Product and Mainstream Health Product (as such terms are defined in the Global Fund C19RM Guidelines) procured outside of the Global Fund's Pooled Procurement Mechanism, the: (i) purchase order issue date; (ii) vendor-promised delivery date; (iii) date of product dispatch from the manufacturer; and (iv) date of product delivery.

- c. The Principal Recipient shall take all appropriate and necessary actions to ensure that any relevant Sub-recipient, supplier, contractor or agent provides the Principal Recipient with such information as may be required for the Principal Recipient to comply with its obligations set out in paragraph (b) above.
7. The Ministry of Health of Nigeria and the CCM shall be responsible for periodically reporting on the COVID-19 burden in accordance with the World Health Organization guidance on Epidemiological and Disease Surveillance and Reporting as part of the Epidemic Preparedness and Response.